This past Monday evening in Berlin, we announced that Apheris and SandboxAQ have launched the Virtual Cell Network. Our goal is to build the world's largest pharma-led virtual cell network.
Late-stage failures are among the costliest outcomes in drug development. Virtual cell m…
전체 보기
This past Monday evening in Berlin, we announced that Apheris and SandboxAQ have launched the Virtual Cell Network. Our goal is to build the world's largest pharma-led virtual cell network.
Late-stage failures are among the costliest outcomes in drug development. Virtual cell models predict how a compound changes a cell, helping teams spot problems earlier. To support decisions in drug programs, these models need data from human-relevant cell systems, measured at the relevant dose and duration, against efficacy and safety endpoints. Much of that data sits inside pharma companies, and no single company holds enough of it alone to train a model that performs reliably on new compounds and cells.
In the Virtual Cell Network, members train AQCell on their proprietary data to broaden its applicability domain, then fine-tune it downstream to make it specific to their own programs. Raw data never leaves any company’s environment.
SandboxAQ provides AQCell. Apheris operates the network and delivers the models through the Apheris platform, so pharma teams can customize them and integrate them into their drug programs. Apheris also runs federated networks for co-folding, ADMET, and antibody developability.
Thank you to everyone who made this launch happen. At SandboxAQ: Nadian Harhen , Bill Fitzgerald, Andrew McLaughlin, Adam Lewis, Zane Beckwith, Nihit Pokhrel, Danielle Scheffey, Radha Patel, and Jennifer Stewart. At Apheris: Robin Röhm, Lewis Mervin, Julian Schoenauer, Iva Lukac, José-Tomás (JT) Prieto, and Max Nisslein.
Founding members can join until the end of Q1 2027.
To learn more or talk to our scientists, see https://t.co/ixA9uErHPB and https://t.co/HLfG15qOGg.